Donation

What Is Iberdomide?

Iberdomide is a CELMoD agent that is being studied in many clinical trials with different drug combinations and in different myeloma patient populations.

What Are CELMoDs?

Cereblon (CRBN) E3 ligase modulators (CELMoDs) are a new drug class in myeloma. The emergence of CELMoDs is building on the well-established platform of immunomodulatory agents. CELMoDs are oral (taken by mouth) medications that have many similarities to immunomodulatory agents. Yet, CELMoDs can be used even in patients who have relapsed after treatment with immunomodulatory agents.

How Is Iberdomide Used in Multiple Myeloma?

While still in clinical trials, iberdomide has demonstrated some positive results. For example, combination therapy with iberdomide and dexamethasone (also called “IBER-dex”) has shown an overall response rate (ORR) of about 30% to 50% in patients with heavily pretreated myeloma. These heavily pretreated patients have undergone 4 to 6 median prior therapies. These patients were triple-class refractory to proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.

Another clinical trial using iberdomide is the phase II study EMN26. This study examines iberdomide maintenance therapy to prolong remission after autologous stem cell
transplantation (ASCT) in newly diagnosed myeloma patients. It demonstrated a favorable safety profile and response improvement at 6 months when compared with Revlimid® (lenalidomide) maintenance.

Also, induction therapy with Kyprolis, iberdomide, and dexamethasone (KID) appears safe. It did not interfere with stem cell mobilization in a phase I/II clinical trial of autologous stem cell transplant (ASCT)-eligible patients with newly diagnosed myeloma. (Note: Induction therapy is the initial treatment given to a patient in preparation for an ASCT.) Additional clinical trial data are being collected.

How Is Iberdomide Administered?

Iberdominde is taken by mouth. It can be combined with other myeloma therapies, such as proteasome inhibitors and monoclonal antibodies.

What Are Potential Side Effects of Iberdomide?

A side effect, also called an adverse event (AE), is an unwanted or unexpected effect caused by a drug. Key risks of iberdomide include the following:

  • Low blood counts (especially neutrophils). This increases the risk of infection.
  • Blood clots. Patients taking iberdomide should be given medication to prevent blood clots.

Patients may also experience low-grade fatigue and diarrhea. The risk of peripheral neuropathy and cardiac complications is low.

Iberdomide has been shown to be associated with Grade 3 infection and anemia, and Grade 3 or 4 neutropenia.

 

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.